The level of procalcitonin is a biomarker for differentiation between pathogenic and non-pathogenic bacteria

Suwipar Deebukkham

doi:10.1016/hscr.v39i2.272156

Authors

Suwipar Deebukkham Department of Medical Technology and Clinical Pathology, Uttaradit Hospital

DOI:

https://doi.org/10.1016/hscr.v39i2.272156

Keywords:

Procalcitonin, Sepsis

Abstract

Background: Sepsis is a condition in which microorganisms such as viruses, fungi, and pathogenic bacteria invade the bloodstream. When the body reacts to the foreign elements of the bacteria, accurate and timely diagnosis will lead to rapid treatment and appropriate antibiotic administration. Therefore, procalcitonin is a biomarker for helping to classify bacterial infections and monitor treatment.
Methods: This is a retrospective description study in a group of samples who underwent medical laboratory tests to measure procalcitonin levels along with blood cultures and were admitted to Uttaradit Hospital between October 1, 2022 and October 31, 2023, totaling 934 cases.
Results: The study found that the procalcitonin level of 0.1-0.5 ng/ml, 26 cases (13.2%), culture results were positive, 491 cases (66.7%), and procalcitonin level of 0.6-2.0 ng/ml had OR = 10.56 (95%CI:6.56-16.99), procalcitonin level >2.0 ng/ml had OR = 17.67 (95%CI: 10.81-28.86), and sexual status had OR1.01 (95%:CI:0.74-1.39), age group between 21-40 years had OR1.20 (95%CI:0.34-4.21), age group
between 41-60 years had OR1.53 (95%CI:0.50-4.68). and the group aged over 60 years had an OR value of 1.80 (95%CI: 0.62-5.27).
Conclusions: Using procalcitonin in conjunction with culture tests can improve diagnostic accuracy and help reduce unnecessary antibiotic use, allowing physicians to diagnose and treat patients promptly

References

Gül F, Arslantaş MK, Cinel İ, Kumar A. Changing Definitions of Sepsis. Turk J Anaesthesiol Reanim. 2017;45(3):129-38.

Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. Jama. 2014;311(13):1308-16.

Fleischmann-Struzek C, Rudd K. Challenges of assessing the burden of sepsis. Medizinische Klinik - Intensivmedizin und Notfallmedizin. 2023;118(2):68-74.

Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. The Lancet. 2020;395(10219):200-11.

Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017;43(3):304-77.

Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29(7):1303-10.

Zilahi G, McMahon MA, Povoa P, Martin-Loeches I. Duration of antibiotic therapy in the intensive care unit. J Thorac Dis. 2016;8(12):3774-80.

Jee Y, Carlson J, Rafai E, Musonda K, Huong TTG, Daza P, et al. Antimicrobial resistance: a threat to global health. Lancet Infect Dis. 2018;18(9):939-40.

Fridkin S, Baggs J, Fagan R, Magill S, Pollack LA, Malpiedi P, et al. Vital signs: improving antibiotic use among hospitalized patients. MMWR Morb Mortal Wkly Rep. 2014;63(9):194-200.

Park IH, Lee SH, Yu ST, Oh YK. Serum procalcitonin as a diagnostic marker of neonatal sepsis. Korean J Pediatr. 2014;57(10):451-6.

Meynaar IA, Droog W, Batstra M, Vreede R, Herbrink P. In Critically Ill Patients, Serum Procalcitonin Is More Useful in Differentiating between Sepsis and SIRS than CRP, Il-6, or LBP. Crit Care Res Pract. 2011;2011:594645.

Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Müller C, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest. 2007;131(1):9-19.

Briel M, Schuetz P, Mueller B, Young J, Schild U, Nusbaumer C, et al. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med. 2008;168(18):2000-7;discussion 7-8.

Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006;173(10):1114-21.

Annane D, Maxime V, Faller JP, Mezher C, Clec’h C, Martel P, et al. Procalcitonin levels to guide antibiotic therapy in adults with non-microbiologically proven apparent severe sepsis: a randomised controlled trial. BMJ Open. 2013;3(2).

de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, et al. Efficacy and safety of procalcitonin

guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. 2016;16(7):819-27.

Mathew B, Roy DD, Kumar TV. The use of procalcitonin as a marker of sepsis in children. J Clin Diagn Res. 2013;7(2):305-7.

Thermo Fisher Scientific. Alinity i BRAHMS PCT [Internet]. Infectious Diseases. Available from: https://

www.thermofisher.com/infectious-diseases/wo/en/procalcitonin/alinity-i-brahms-PCT.html

Alinity i B∙R∙A∙H∙M∙S PCT Reagent Kit (also referred to as PCT). November 2017. p. 1-8. Available from: https://www.thermofisher.com/infectious-diseases/wo/

en/procalcitonin/alinity-i-brahms-PCT.html

Alinity i B∙R∙A∙H∙M∙S PCT Controls (also referred to as PCT Ctrls). Revised June 2018. Produced for Abbott by Abbott Ireland Diagnostics Division, Sligo, Ireland. Available from: https://www.abbottdiagnostics.com.

Blood Culture. BIOMERIEUX. Available from https://www.biomerieux-usa.com/bactalert3d/automatedsystem

University of Nebraska Medical Center, Department of Internal Medicine. Procalcitonin Guidance Document

[Internet]. Omaha: UNMC; [cited 2024 Dec 12]. Available from: https://www.unmc.edu/intmed/_documents/id/asp/news/procalcitonin-guidance.pdf